The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Scientists at Gladstone Institutes and UC San Francisco (UCSF) have mapped the intricate network of genetic switches that ...

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...